Pharming Group (NASDAQ:PHAR) Short Interest Down 68.4% in January

Pharming Group (NASDAQ:PHAR) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 7,500 shares, a decrease of 68.4% from the January 15th total of 23,700 shares. Based on an average daily trading volume, of 7,200 shares, the days-to-cover ratio is currently 1.0 days.

Pharming Group Price Performance

Shares of PHAR traded up $0.30 during mid-day trading on Wednesday, hitting $8.86. 3,236 shares of the company traded hands, compared to its average volume of 6,544. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $602.68 million, a price-to-earnings ratio of -34.07 and a beta of -0.10. The business has a 50-day moving average of $9.26 and a 200 day moving average of $8.43. Pharming Group has a one year low of $6.65 and a one year high of $12.29.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PHAR. Jefferies Financial Group initiated coverage on Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. Oppenheimer reduced their price objective on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.